Actively Recruiting
Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma
Led by Emory University · Updated on 2026-03-02
12
Participants Needed
1
Research Sites
65 weeks
Total Duration
On this page
Sponsors
E
Emory University
Lead Sponsor
G
Genentech, Inc.
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study aims to determine the safety and tolerability of combined Atezolizumab, stereotactic body radiation therapy (SBRT), and surgical resection of pulmonary metastases in patients with pulmonary recurrence of osteosarcoma
CONDITIONS
Official Title
Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologic verification of osteosarcoma at original diagnosis or relapse
- In first or greater relapse of osteosarcoma
- Lung-only recurrence (unilateral or bilateral)
- All pulmonary nodules must be resectable without pneumonectomy
- At least one lesion 5 mm suitable for SBRT plus additional nodules meeting surgical criteria
- Lansky or Karnofsky score �b0 60, or ECOG performance score �b2 2
- All prior treatment toxicities resolved to Grade �b1 or clinically stable
- Specific waiting periods after prior treatments before enrollment
- Adequate bone marrow, renal, liver, pancreatic, thyroid, pulmonary, and cardiac function
- Urine protein within defined limits
- Life expectancy of at least 4 months
- Negative pregnancy test for women of childbearing potential
- Use of effective contraception during study participation and for 5 months after last dose
- Signed informed consent and assent if applicable
You will not qualify if you...
- Pregnancy or breast-feeding
- Active metastatic disease outside lungs including bone, CNS, or other sites
- Greater than Grade 1 pleural effusion
- Prior lung radiation
- Active or severe autoimmune disorders requiring systemic treatment recently or historically
- Significant cardiovascular disease within 3 months before treatment
- Active tuberculosis
- Medical conditions risking surgery or protocol compliance
- Chronic immunosuppressive therapy use
- Uncontrolled infection
- Prior allogeneic stem cell or solid organ transplant
- Currently receiving other investigational or anti-cancer agents
- Known HIV, hepatitis B, or hepatitis C infection
- Current or prior pneumonitis
- Live or attenuated vaccine within 30 days of enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chilldren's Healthcare of Atlanta
Atlanta, Georgia, United States, 30322
Actively Recruiting
Research Team
T
Thomas Cash, MD, MSc
CONTACT
C
Chloe Edgerton
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here